project id: TCGA-TGCT; case submitter id: TCGA-XE-AAOB; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.75; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.19; rna integrity number: 7.1; age at index: 27; days to birth: -9907; days to death: 513; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1981; year of death: 2009; age at diagnosis: 9907; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage IS; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: NX; ajcc pathologic stage: Stage IS; ajcc pathologic t: T1; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C62.90; igcccg stage: Intermediate Prognosis; last known disease status: not reported; morphology: 9081/3; primary diagnosis: Teratocarcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1966; days to sample procurement: 0; initial weight: 660.0; portion submitter id: TCGA-XE-AAOB-01A-11; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0;